26 rue d’Ulm
The open position is in line with recent developments and an effort to strengthen the interface between immunology, single-cell technologies and bioinformatics. The postdoctoral fellow will be cosupervised by Sebastian Amigorena, director of the “Immunity and Cancer” Unit at the Institut Curie, and Prof. Andrew Griffiths, director of the Laboratory of Biochemistry (LBC) at the ESPCI.
Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Despite the improved patient survival achieved with the advent of immunotherapies, about 60-70% of patients don’t respond to treatment or relapse later on. This
underscores the need for understanding the evasion/resistance immune mechanisms within the tumor microenvironment (including myeloid cells and T lymphocytes) that hinder an effective anti-tumor immunity.
We are developing a prototype droplet-based microfluidics system for single-cell transcriptomic, epigenetic and phenotypic analysis as well as paired TCR α-β chain sequencing of immune cells. This powerful droplet-based microfluidics system will provide unprecedented information on single-cell heterogeneity of tumor-infiltrating immune cells and the complexity of their interactions with other cells within the tumor, thereby paving the way for cancer biomarker and therapeutic target discovery.
The candidate will apply bioinformatics analysis on transcriptomic (scRNA-Seq), epigenetic (scChIP-Seq) and phenotypic (Ab-Seq) data to improve our understanding of the evasion/resistance immune mechanisms within the tumor microenvironment.
In close collaboration with wet lab postdocs and students, the candidate will help design experiments and will be in charge of integrating and interpreting comprehensive next generation sequencing datasets:
- Single-cell NSG data (including ChIP-Seq and RNA-Seq)
- Pathways and Enrichment analyses (Networks, Functional, Transcription Factor Binding Sites…).
He/she will benefit from strong interactions within the bioinformatics team in the “Immunity and Cancer” unit headed by Sebastian Amigorena (15 people) and in the LBC/ESPCI headed by Andrew Griffiths (25 people)